Gyre Therapeutics Emerges as a Notable Player in Liver Fibrosis Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 26 2025
0mins
Should l Buy MDGL?
Source: Benzinga
Gyre Therapeutics Overview: Gyre Therapeutics Inc. is a biopharmaceutical company focusing on organ fibrosis treatments, with its flagship product ETUARY being the first approved treatment for idiopathic pulmonary fibrosis in China.
Financial Performance: The company reported second-quarter sales of $26.78 million, falling short of expectations, but anticipates revenue growth in 2025 driven by new product launches and existing sales.
Hydronidone Development: Gyre's lead asset, hydronidone, has shown promising results in clinical trials for liver fibrosis and is expected to enter Phase 2 assessment in the U.S. by late 2025, with plans for accelerated approval in China.
Market Potential: Analysts predict significant market potential for hydronidone, estimating it could generate approximately $6 billion in annual sales by 2033, similar to the success anticipated for Madrigal Pharmaceuticals' recent liver disease treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDGL
Wall Street analysts forecast MDGL stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 435.620
Low
527.00
Averages
636.22
High
900.00
Current: 435.620
Low
527.00
Averages
636.22
High
900.00
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Madrigal (MDGL) Q4 2025 Earnings Call Transcript
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported a purchase of 2,005,813 shares of Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Market Value Growth: The fund's quarter-end position in Kymera Therapeutics increased by $297.15 million due to this purchase, reflecting the dual impact of trading activity and share price appreciation, further solidifying its market position.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, marking a 130% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: With approximately $1.6 billion in cash at the beginning of 2026, Kymera supports its leading oral immunology pipeline, which is expected to drive sustained growth for the company in the coming years.
See More
U.S. Markets Fell on Thursday; Klarna Group Reported Largest Loss
- U.S. Stock Market Performance: Stock indexes in the U.S. experienced a decline on Thursday, with the overall market falling by 0.54%.
- Specific Index Movements: The S&P 500 index decreased by 0.31%, while the Dow Jones Industrial Average dropped by 0.28%.
See More
Madrigal Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Sales Performance: Madrigal Pharmaceuticals reported net sales of $321 million in Q4 2025, more than tripling from Q4 2024, with full-year net sales reaching $958.4 million, demonstrating strong market demand for Rezdiffra as a foundational therapy.
- Sustained Patient Growth: The number of patients on Rezdiffra exceeded 36,250 by the end of Q4 2025, up from over 29,500 in Q3, indicating the company's success in patient acquisition and market penetration.
- Increased R&D and Expenses: R&D expenses for Q4 2025 were $116.3 million, totaling $388.5 million for the year, primarily driven by upfront payments for new pipeline assets, which are expected to propel future product development and market expansion.
- Optimistic Future Outlook: CFO Dier anticipates robust net sales growth in 2026, despite an increase in gross-to-net impact into the high 30% range due to contracting, indicating the company’s strong growth potential in a competitive market.
See More
Madrigal Pharmaceuticals Reports Mixed Q4 2025 Earnings
- Mixed Financial Results: Madrigal Pharmaceuticals reported a Q4 2025 revenue of $321.1 million, reflecting over 210% year-over-year growth and beating consensus by $8.3 million, yet a loss per share of $2.57 missed analysts' expectations by $2.03, leading to an approximately 8% premarket decline in stock price.
- Rezdiffra Market Performance: The FDA-approved therapy for metabolic dysfunction-associated steatohepatitis, Rezdiffra, generated $958.4 million in 2025, with over 36,250 patients treated, indicating strong market demand and acceptance of the product.
- Significant Revenue Growth: Madrigal achieved over 400% year-over-year growth in net revenue for 2025, while net loss decreased by more than 38% to $288.2 million, demonstrating a balance between revenue growth and cost management, with potential for further financial improvement.
- Liquidity Concerns: As of December 31, the company's cash and cash equivalents reached $988.6 million, reflecting approximately 6% year-over-year growth, but fell short of the $1.17 billion projected by analysts, highlighting pressures from debt repayment and operational funding needs.
See More
Madrigal Pharmaceuticals Q4 2025 Earnings Analysis
- Earnings Performance: Madrigal Pharmaceuticals reported a Q4 2025 GAAP EPS of -$2.57, missing expectations by $2.03, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The quarter's revenue reached $321.08 million, reflecting a 210.8% year-over-year increase and exceeding market expectations by $8.34 million, suggesting significant progress in product sales that could lay the groundwork for future growth.
- Cash Position: As of December 31, 2025, Madrigal had cash, cash equivalents, restricted cash, and marketable securities totaling $988.6 million, an increase from $931.3 million in 2024, primarily due to the introduction of a new credit facility in July 2025, enhancing the company's financial flexibility.
- Financing Context: The new credit facility includes a $350 million initial term loan, with a portion used to repay outstanding loan obligations, yet attention is needed on the utilization of operational funds to ensure ongoing financial health.
See More
Madrigal (MDGL) Q4 2025 Earnings Call Transcript
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported a purchase of 2,005,813 shares of Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Market Value Growth: The fund's quarter-end position in Kymera Therapeutics increased by $297.15 million due to this purchase, reflecting the dual impact of trading activity and share price appreciation, further solidifying its market position.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, marking a 130% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: With approximately $1.6 billion in cash at the beginning of 2026, Kymera supports its leading oral immunology pipeline, which is expected to drive sustained growth for the company in the coming years.
See More
U.S. Markets Fell on Thursday; Klarna Group Reported Largest Loss
- U.S. Stock Market Performance: Stock indexes in the U.S. experienced a decline on Thursday, with the overall market falling by 0.54%.
- Specific Index Movements: The S&P 500 index decreased by 0.31%, while the Dow Jones Industrial Average dropped by 0.28%.
See More
Madrigal Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Sales Performance: Madrigal Pharmaceuticals reported net sales of $321 million in Q4 2025, more than tripling from Q4 2024, with full-year net sales reaching $958.4 million, demonstrating strong market demand for Rezdiffra as a foundational therapy.
- Sustained Patient Growth: The number of patients on Rezdiffra exceeded 36,250 by the end of Q4 2025, up from over 29,500 in Q3, indicating the company's success in patient acquisition and market penetration.
- Increased R&D and Expenses: R&D expenses for Q4 2025 were $116.3 million, totaling $388.5 million for the year, primarily driven by upfront payments for new pipeline assets, which are expected to propel future product development and market expansion.
- Optimistic Future Outlook: CFO Dier anticipates robust net sales growth in 2026, despite an increase in gross-to-net impact into the high 30% range due to contracting, indicating the company’s strong growth potential in a competitive market.
See More
Madrigal Pharmaceuticals Reports Mixed Q4 2025 Earnings
- Mixed Financial Results: Madrigal Pharmaceuticals reported a Q4 2025 revenue of $321.1 million, reflecting over 210% year-over-year growth and beating consensus by $8.3 million, yet a loss per share of $2.57 missed analysts' expectations by $2.03, leading to an approximately 8% premarket decline in stock price.
- Rezdiffra Market Performance: The FDA-approved therapy for metabolic dysfunction-associated steatohepatitis, Rezdiffra, generated $958.4 million in 2025, with over 36,250 patients treated, indicating strong market demand and acceptance of the product.
- Significant Revenue Growth: Madrigal achieved over 400% year-over-year growth in net revenue for 2025, while net loss decreased by more than 38% to $288.2 million, demonstrating a balance between revenue growth and cost management, with potential for further financial improvement.
- Liquidity Concerns: As of December 31, the company's cash and cash equivalents reached $988.6 million, reflecting approximately 6% year-over-year growth, but fell short of the $1.17 billion projected by analysts, highlighting pressures from debt repayment and operational funding needs.
See More
Madrigal Pharmaceuticals Q4 2025 Earnings Analysis
- Earnings Performance: Madrigal Pharmaceuticals reported a Q4 2025 GAAP EPS of -$2.57, missing expectations by $2.03, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The quarter's revenue reached $321.08 million, reflecting a 210.8% year-over-year increase and exceeding market expectations by $8.34 million, suggesting significant progress in product sales that could lay the groundwork for future growth.
- Cash Position: As of December 31, 2025, Madrigal had cash, cash equivalents, restricted cash, and marketable securities totaling $988.6 million, an increase from $931.3 million in 2024, primarily due to the introduction of a new credit facility in July 2025, enhancing the company's financial flexibility.
- Financing Context: The new credit facility includes a $350 million initial term loan, with a portion used to repay outstanding loan obligations, yet attention is needed on the utilization of operational funds to ensure ongoing financial health.
See More
